These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 32220085)

  • 21. I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease.
    Park JH; Cho B; Kwon H; Prilutsky D; Yun JM; Choi HC; Hwang KB; Lee IH; Kim JI; Kong SW
    Liver Int; 2015 Dec; 35(12):2537-46. PubMed ID: 26148225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.
    Chen LZ; Xin YN; Geng N; Jiang M; Zhang DD; Xuan SY
    World J Gastroenterol; 2015 Jan; 21(3):794-802. PubMed ID: 25624712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification and Optimization of a Minor Allele-Specific siRNA to Prevent PNPLA3 I148M-Driven Nonalcoholic Fatty Liver Disease.
    Murray JK; Long J; Liu L; Singh S; Pruitt D; Ollmann M; Swearingen E; Hardy M; Homann O; Wu B; Holder JR; Sham K; Herberich B; Lo MC; Dou H; Shkumatov A; Florio M; Rulifson IC
    Nucleic Acid Ther; 2021 Oct; 31(5):324-340. PubMed ID: 34297902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.
    Valenti L; Al-Serri A; Daly AK; Galmozzi E; Rametta R; Dongiovanni P; Nobili V; Mozzi E; Roviaro G; Vanni E; Bugianesi E; Maggioni M; Fracanzani AL; Fargion S; Day CP
    Hepatology; 2010 Apr; 51(4):1209-17. PubMed ID: 20373368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between rs738409 polymorphism in patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene and hepatocellular carcinoma susceptibility: Evidence from case-control studies.
    Li JF; Zheng EQ; Xie M
    Gene; 2019 Feb; 685():143-148. PubMed ID: 30403964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
    Donati B; Motta BM; Pingitore P; Meroni M; Pietrelli A; Alisi A; Petta S; Xing C; Dongiovanni P; del Menico B; Rametta R; Mancina RM; Badiali S; Fracanzani AL; Craxì A; Fargion S; Nobili V; Romeo S; Valenti L
    Hepatology; 2016 Mar; 63(3):787-98. PubMed ID: 26605757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of PNPLA3 polymorphism as gain in function mutation in the pathogenesis of non-alcoholic fatty liver disease.
    Delik A; Akkız H; Dinçer S
    Indian J Gastroenterol; 2020 Feb; 39(1):84-91. PubMed ID: 32333362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease.
    Hotta K; Yoneda M; Hyogo H; Ochi H; Mizusawa S; Ueno T; Chayama K; Nakajima A; Nakao K; Sekine A
    BMC Med Genet; 2010 Dec; 11():172. PubMed ID: 21176169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of liver fibrosis with extrahepatic cancer in steatotic liver disease patients with PNPLA3 I148M GG genotype.
    Tai J; Hsu CW; Chen WT; Yang SS; Chiu CH; Chien RN; Chang ML
    Cancer Sci; 2024 Feb; 115(2):564-574. PubMed ID: 38083881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combining I148M and E167K variants to improve risk prediction for nonalcoholic fatty liver disease in Qingdao Han population, China.
    Chen LZ; Ding HY; Liu SS; Liu Q; Jiang XJ; Xin YN; Xuan SY
    Lipids Health Dis; 2019 Feb; 18(1):45. PubMed ID: 30738435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants.
    Del Ben M; Polimeni L; Brancorsini M; Di Costanzo A; D'Erasmo L; Baratta F; Loffredo L; Pastori D; Pignatelli P; Violi F; Arca M; Angelico F
    Eur J Intern Med; 2014 Jul; 25(6):566-70. PubMed ID: 24947770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A common variant in the PNPLA3 gene is a risk factor for non-alcoholic fatty liver disease in obese Taiwanese children.
    Lin YC; Chang PF; Hu FC; Yang WS; Chang MH; Ni YH
    J Pediatr; 2011 May; 158(5):740-4. PubMed ID: 21168155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels.
    Sun DQ; Zheng KI; Xu G; Ma HL; Zhang HY; Pan XY; Zhu PW; Wang XD; Targher G; Byrne CD; Chen YP; Yuan WJ; Zheng MH
    Liver Int; 2020 Jan; 40(1):107-119. PubMed ID: 31519069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
    Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
    Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis.
    Finkenstedt A; Auer C; Glodny B; Posch U; Steitzer H; Lanzer G; Pratschke J; Biebl M; Steurer M; Graziadei I; Vogel W; Zoller H
    Clin Gastroenterol Hepatol; 2013 Dec; 11(12):1667-72. PubMed ID: 23872669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease.
    Valenti L; Alisi A; Galmozzi E; Bartuli A; Del Menico B; Alterio A; Dongiovanni P; Fargion S; Nobili V
    Hepatology; 2010 Oct; 52(4):1274-80. PubMed ID: 20648474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings.
    Mantovani A; Taliento A; Zusi C; Baselli G; Prati D; Granata S; Zaza G; Colecchia A; Maffeis C; Byrne CD; Valenti L; Targher G
    Liver Int; 2020 May; 40(5):1130-1141. PubMed ID: 32125756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of the I148M/PNPLA3 (rs738409) polymorphism with premature coronary artery disease, fatty liver, and insulin resistance in type 2 diabetic patients and healthy controls. The GEA study.
    Posadas-Sánchez R; López-Uribe ÁR; Posadas-Romero C; Pérez-Hernández N; Rodríguez-Pérez JM; Ocampo-Arcos WA; Fragoso JM; Cardoso-Saldaña G; Vargas-Alarcón G
    Immunobiology; 2017 Oct; 222(10):960-966. PubMed ID: 27615511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between the PNPLA3 I148M polymorphism and non-alcoholic fatty liver disease in the Uygur and Han ethnic groups of northwestern China.
    Zhang Y; Cai W; Song J; Miao L; Zhang B; Xu Q; Zhang L; Yao H
    PLoS One; 2014; 9(10):e108381. PubMed ID: 25290313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PNPLA3 I148M variant affects non-alcoholic fatty liver disease in liver transplant recipients.
    Liu ZT; Chen TC; Lu XX; Cheng J; Xie HY; Zhou L; Zheng SS
    World J Gastroenterol; 2015 Sep; 21(34):10054-6. PubMed ID: 26379412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.